A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

European Journal of Cancer

Volumn 49, Issue 8, 2013, Pages 1799-1807

  Soria, Jean Charles ^a   Massard, Christophe ^a   Lazar, Vladimir ^a   Ozoux, Marie Laure ^b   Mery Mignard, Dominique ^b   Deslandes, Antoine ^b   Tolcher, Anthony W ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SANOFI   (France)

^c South Texas Accelerated Research Therapeutics (START)   (United States)

Author keywords

Breast cancer; IGF 1; IGF 1R; Monoclonal antibody; Sarcoma

Indexed keywords

AVE 1642; DOCETAXEL; DRUG ANTIBODY;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BONE TUMOR; CLINICAL ARTICLE; COLON CANCER; CONSTIPATION; CYTOLYTIC HEPATITIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; ESOPHAGITIS; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATOBILIARY DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOGENICITY; LACRIMATION; MALE; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; MYALGIA; MYOSITIS; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRESYNCOPE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SARCOMA; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINE RETENTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; RECEPTOR, IGF TYPE 1; SARCOMA; TAXOIDS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84876687095     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.01.003     Document Type: Article

References (20)

1. M.N. Pollak, E.S. Schernhammer, and S.E. Hankinson Insulin-like growth factors and neoplasia Nat Rev Cancer 4 7 2004 505 518 [review. No abstract available]
2. M.N. Pollak, J.F. Perdue, R.G. Margolese, K. Baer, and M. Richard Presence of somatomedin receptors on primary human breast and colon carcinomas Cancer Lett 38 1-2 1987 223 230
3. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors Cancer Cell 5 3 2004 221 230
4. C. Sell, M. Rubini, and R. Rubin Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor Proc Natl Acad Sci USA 90 23 1993 11217 11221
5. H. Hartog, J. Wesseling, and B.H. Marike The insulin-like growth factor 1 receptor in cancer: old focus, new future Eur J Cancer 43 2007 1895 1904
6. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat Rev Cancer 8 12 2008 915 928 [Review. Erratum in: Nat Rev Cancer 2009;9(3):224]
7. P. Haluska, J.M. Carboni, and D.A. Loegering In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417 Cancer Res 66 1 2006 362 371
8. E.K. Maloney, J.L. McLaughlin, and N.E. Dagdigian An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation Cancer Res 63 16 2003 5073 5083
9. S.M. Huang, H. Zhao, and J.I. Lee Therapeutic protein-drug interactions and implications for drug development Clin Pharmacol Ther 87 4 2010 497 503 [epub 2010, March 3]
10. D.D. Karp, L.G. Paz-Ares, and S. Novello Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 15 2009 2516 2522 [epub 2009, April 20]
11. E.K. Rowinsky, H. Youssoufian, and J.R. Tonra Row IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor Clin Cancer Res 13 18 Pt. 2 2007 5549s 5555s [review]
12. P. Haluska, H.M. Shaw, and G.N. Batzel Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors Clin Cancer Res 13 19 2007 5834 5840
13. P. Haluska, F. Worden, and D. Olmos Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Cancer Chemother Pharmacol 2009 [epub ahead of print]
14. D.D. Karp, M.N. Pollak, and R.B. Cohen Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin J Thorac Oncol 2009
15. A. Gualberto, and M. Pollak Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions Oncogene 28 34 2009 3009 3021
16. D. Olmos, S. Postel-Vinay, and L.R. Molife Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study Lancet Oncol 11 2 2010 129 135 [epub 2009, December 23]
17. J.S. de Bono, G. Attard, and A. Adjei Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor Clin Cancer Res 13 12 2007 3611 3616
18. C.P. Carden, L.R. Molife, and J.S. de Bono Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor Mol Cancer Ther 8 8 2009 2077 2078 [epub 2009, August 11. No abstract available]
19. M.M. Chitnis, J.S. Yuen, and A.S. Protheroe The type 1 insulin-like growth factor receptor pathway Clin Cancer Res 14 20 2008 6364 6370 [review]
20. A. Gualberto, C.L. Melvin, and A. Dean Characterization of NSCLC patients responding to anti-IGF-IR therapy J Clin Oncol 26 Suppl. 2008 [abstr. 8000]